(Q36237906)

13 August 2017

1 reference

title

Biosafety evaluation of recombinant live oral bacterial vaccines in the context of European regulation (English)

1 reference

13 August 2017

Didier Favre

1

1 reference

13 August 2017

Jean-François Viret

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

2 August 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

24

1 reference

13 August 2017

issue

18

1 reference

13 August 2017

page(s)

3856-3864

1 reference

The mucosal immune system: from fundamental concepts to vaccine development

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Isolation and Characterization of Gal E Mutant Ty 21a of Salmonella typhi: A Candidate Strain for a Live, Oral Typhoid Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Suicidal genetic elements and their use in biological containment of bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Virulence and vaccine potential of Salmonella typhimurium mutants deficient in the expression of the RpoS (sigma S) regulon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Construction of genetically marked Vibrio cholerae O1 vaccine strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Further molecular characterization and stability of the live oral attenuated cholera vaccine strain CVD103-HgR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

inferred from DOI database lookup

7 January 2021

based on heuristic

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.018

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.07.018

1 reference

13 August 2017

1 reference